GenTrust’s Bristol-Myers Squibb BMY Stock Holding History

GenTrust’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,706	Closed	-$1.2M	–	210
2026 Q1	$1.2M	Buy	19,706 +5,286	+37%	+$308K	0.05%	96
2025 Q4	$778K	Buy	+14,420	New	+$694K	0.03%	131

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GenTrust's BMY Position: Q2 2026 in Review

GenTrust sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 19,706 shares — an estimated $1.2M sold.

GenTrust first reported a position in BMY in Q4 2025 and held it in 2 quarters. The position peaked at $1.2M in Q1 2026. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

GenTrust reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
GenTrust sold 19,706 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.2M.
GenTrust first reported a position in Bristol-Myers Squibb in Q4 2025 and held it in 2 quarters.
GenTrust's Bristol-Myers Squibb position peaked at $1.2M in Q1 2026.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on GenTrust's 13F filing for Q2 2026, filed 6 Aug 2026.